Dr. Melinda L. Yushak
Claim this profileEmory University Hospital/Winship Cancer Institute
Studies Cancer
Studies Melanoma
11 reported clinical trials
24 drugs studied
Area of expertise
1Cancer
Stage IV
Stage III
Stage I
2Melanoma
Stage IV
BRAF positive
Stage III
Affiliated Hospitals
Clinical Trials Melinda L. Yushak is currently running
Propranolol + Pembrolizumab
for Skin Cancer
This phase Ib/II trial studies the side effects and best dose of propranolol hydrochloride when given together with pembrolizumab and how well they work in treating patients with stage IIIC-IV melanoma that cannot be removed by surgery. Pembrolizumab is a monoclonal antibody that "takes the brakes off the immune system" and thus allows for anti-tumor immune responses. Propranolol hydrochloride is a beta adrenergic blocking agent that can enhance immune cell responses when under stress. Giving propranolol hydrochloride and pembrolizumab may work better in treating patients with melanoma.
Recruiting3 awards Phase 1 & 211 criteria
Tuvusertib + Avelumab
for Merkel Cell Skin Cancer
This phase II trial compares tuvusertib in combination with avelumab to tuvusertib alone to determine whether the combination therapy will lengthen the time before the cancer starts getting worse in patients with Merkel cell cancer that has not responded to previous treatment (refractory). Tuvusertib is a drug that inhibits an enzyme called ataxia telangiectasia and Rad3 related (ATR) kinase, which is an enzyme that plays a role in repair of damaged deoxyribonucleic acid (DNA) as well as tumor cell replication and survival. It may lead to tumor cell death by inhibiting ATR kinase activity. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving tuvusertib in combination with avelumab may lengthen the time before Merkel cell cancer starts getting worse compared to giving avelumab alone.
Recruiting1 award Phase 210 criteria
More about Melinda L. Yushak
Clinical Trial Related6 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Melinda L. Yushak has experience with
- Nivolumab
- Ipilimumab
- Pembrolizumab
- Dabrafenib Mesylate
- Trametinib Dimethyl Sulfoxide
- Cemiplimab
Breakdown of trials Melinda L. Yushak has run
Cancer
Melanoma
Skin Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Melinda L. Yushak specialize in?
Melinda L. Yushak focuses on Cancer and Melanoma. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is Melinda L. Yushak currently recruiting for clinical trials?
Yes, Melinda L. Yushak is currently recruiting for 5 clinical trials in Atlanta Georgia. If you're interested in participating, you should apply.
Are there any treatments that Melinda L. Yushak has studied deeply?
Yes, Melinda L. Yushak has studied treatments such as Nivolumab, Ipilimumab, Pembrolizumab.
What is the best way to schedule an appointment with Melinda L. Yushak?
Apply for one of the trials that Melinda L. Yushak is conducting.
What is the office address of Melinda L. Yushak?
The office of Melinda L. Yushak is located at: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia 30322 United States. This is the address for their practice at the Emory University Hospital/Winship Cancer Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.